Provided by Tiger Trade Technology Pte. Ltd.

Biogen

222.15
-0.7400-0.33%
Post-market: 222.150.00000.00%17:40 EDT
Volume:1.30M
Turnover:291.03M
Market Cap:32.80B
PE:39.46
High:228.00
Open:222.93
Low:221.40
Close:222.89
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.07
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.74
PE(LYR):25.27

Loading ...

How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)

Simply Wall St.
·
2 hours ago

Pharma Stocks Rally With Amgen, Gilead Sciences up 3%

Tiger Newspress
·
Yesterday

AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?

TIPRANKS
·
Yesterday

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Yesterday

Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed

TIPRANKS
·
Oct 06

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)

TIPRANKS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Oct 03

Biogen Says Litifilimab Safety Profile Consistent with no New Safety Signals Identified

Reuters
·
Oct 03

Biogen's Experimental Lupus Drug Shows Benefit Against Skin Symptoms

Reuters
·
Oct 03

Biogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook

TIPRANKS
·
Oct 03

Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study

Reuters
·
Oct 02

Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52

THOMSON REUTERS
·
Oct 02

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~

THOMSON REUTERS
·
Oct 02